1. Home
  2. BRUN vs AVLN Comparison

BRUN vs AVLN Comparison

Compare BRUN & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRUN

Boost Run Inc. Class A Common Stock

N/A

Current Price

$20.70

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$28.19

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BRUN
AVLN
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
BRUN
AVLN
Price
$20.70
$28.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.7M
237.7K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.58
$24.90
52 Week High
$40.46
$33.32

Technical Indicators

Market Signals
Indicator
BRUN
AVLN
Relative Strength Index (RSI) 37.67 43.06
Support Level $15.58 $26.38
Resistance Level $26.45 $30.45
Average True Range (ATR) 2.44 1.96
MACD -0.16 0.19
Stochastic Oscillator 45.91 58.02

Price Performance

Historical Comparison
BRUN
AVLN

About BRUN Boost Run Inc. Class A Common Stock

Boost Run Inc is an NVIDIA Cloud Provider. Its platform provides GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. Enterprises rely on Boost Run to power their main demanding AI workloads with the performance, security, and reliability their operations require. The group maintains SOC 2 Type II, HIPAA, ISO 27001, and ISO 27701 certifications at the operator level, and partners with data center facilities that uphold equivalent security and compliance standards.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: